Wolfe Research Downgrades ResMed to Peer Perform
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Mike Polark has downgraded ResMed (NYSE:RMD) from Outperform to Peer Perform.

September 29, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed has been downgraded from Outperform to Peer Perform by Wolfe Research.
Analyst ratings often have a direct impact on a company's stock price. A downgrade from Outperform to Peer Perform suggests that the analyst believes the company's stock will perform similarly to other companies in the industry, rather than outperforming them. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100